Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects

Next Previous
Trial Profile

Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanabecestat (Primary) ; Dabigatran etexilate
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

Most Recent Events

  • 18 Dec 2019 Results, assessing the interaction between dabigatran etexilate and lanabecestat when they are taken together, published in the Journal of Clinical Pharmacology
  • 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 25 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top